Cost–Benefit Analysis of Novel Antiviral Ritonavir in the Active Duty U.S. Military Population

Cost–Benefit Analysis of Novel Antiviral Ritonavir in the Active Duty U.S. Military Population

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Military medicine 2022-08, Vol.187 (9-10), p.274-275
Hauptverfasser: Morrison Ponce, Daphne, Kitchen, Levi K, Devlin, John J
Format: Artikel
Sprache:eng
Schlagworte:
Antiviral Agents - therapeutic use
Cost-Benefit Analysis
Humans
Military Personnel
Ritonavir - pharmacology
Ritonavir - therapeutic use
United States
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 275
container_issue 9-10
container_start_page 274
container_title Military medicine
container_volume 187
creator Morrison Ponce, Daphne
Kitchen, Levi K
Devlin, John J
description
doi_str_mv 10.1093/milmed/usab552
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2617273924</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/milmed/usab552</oup_id><sourcerecordid>2617273924</sourcerecordid><originalsourceid>FETCH-LOGICAL-c397t-90721194fdfebff3da71ffce9d7331261924b00cddde149e45917ba4c05c87663</originalsourceid><addsrcrecordid>eNqFkLtOwzAUhi0EoqWwMiJLLDAkteMkrsdSrlK5CKjEFpzEFq7cOMROpW68A2_Ik-Aq7cLCdKxzPn_S_wNwjFGIESPDhdILUQ5by_MkiXZAHzOCghSTt13QRyhKgxjRpAcOrJ0jhGM2wvugR_xMoxj1wfvEWPfz9X0hKiGVg-OK65VVFhoJH8xSaL9xaqkaruGzcqbi_g1VBd2HgOPCnwS8bN0KzsKXEN4rrRxvVvDJ1K3mTpnqEOxJrq042swBmF1fvU5ug-njzd1kPA0KwqgLGKIRxiyWpRS5lKTkFEtZCFZSQnCUYhbFOUJFWZbCpxBxwjDNeVygpBjRNCUDcNZ568Z8tsK6bKFsIbTmlTCtzbyCRpR4jUdP_6Bz0zY-uKcoojRN4hHzVNhRRWOsbYTM6kYtfLgMo2zdfdZ1n2269x9ONto2X--3-LZsD5x3gGnr_2S_GUmQtA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2707765489</pqid></control><display><type>article</type><title>Cost–Benefit Analysis of Novel Antiviral Ritonavir in the Active Duty U.S. Military Population</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Morrison Ponce, Daphne ; Kitchen, Levi K ; Devlin, John J</creator><creatorcontrib>Morrison Ponce, Daphne ; Kitchen, Levi K ; Devlin, John J</creatorcontrib><identifier>ISSN: 0026-4075</identifier><identifier>EISSN: 1930-613X</identifier><identifier>DOI: 10.1093/milmed/usab552</identifier><identifier>PMID: 34986240</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Antiviral Agents - therapeutic use ; Cost-Benefit Analysis ; Humans ; Military Personnel ; Ritonavir - pharmacology ; Ritonavir - therapeutic use ; United States</subject><ispartof>Military medicine, 2022-08, Vol.187 (9-10), p.274-275</ispartof><rights>Published by Oxford University Press on behalf of the Association of Military Surgeons of the United States 2021. This work is written by (a) US Government employee(s) and is in the public domain in the US. 2021</rights><rights>Published by Oxford University Press on behalf of the Association of Military Surgeons of the United States 2021. This work is written by (a) US Government employee(s) and is in the public domain in the US.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c397t-90721194fdfebff3da71ffce9d7331261924b00cddde149e45917ba4c05c87663</citedby><orcidid>0000-0002-6191-643X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1584,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34986240$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Morrison Ponce, Daphne</creatorcontrib><creatorcontrib>Kitchen, Levi K</creatorcontrib><creatorcontrib>Devlin, John J</creatorcontrib><title>Cost–Benefit Analysis of Novel Antiviral Ritonavir in the Active Duty U.S. Military Population</title><title>Military medicine</title><addtitle>Mil Med</addtitle><subject>Antiviral Agents - therapeutic use</subject><subject>Cost-Benefit Analysis</subject><subject>Humans</subject><subject>Military Personnel</subject><subject>Ritonavir - pharmacology</subject><subject>Ritonavir - therapeutic use</subject><subject>United States</subject><issn>0026-4075</issn><issn>1930-613X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkLtOwzAUhi0EoqWwMiJLLDAkteMkrsdSrlK5CKjEFpzEFq7cOMROpW68A2_Ik-Aq7cLCdKxzPn_S_wNwjFGIESPDhdILUQ5by_MkiXZAHzOCghSTt13QRyhKgxjRpAcOrJ0jhGM2wvugR_xMoxj1wfvEWPfz9X0hKiGVg-OK65VVFhoJH8xSaL9xaqkaruGzcqbi_g1VBd2HgOPCnwS8bN0KzsKXEN4rrRxvVvDJ1K3mTpnqEOxJrq042swBmF1fvU5ug-njzd1kPA0KwqgLGKIRxiyWpRS5lKTkFEtZCFZSQnCUYhbFOUJFWZbCpxBxwjDNeVygpBjRNCUDcNZ568Z8tsK6bKFsIbTmlTCtzbyCRpR4jUdP_6Bz0zY-uKcoojRN4hHzVNhRRWOsbYTM6kYtfLgMo2zdfdZ1n2269x9ONto2X--3-LZsD5x3gGnr_2S_GUmQtA</recordid><startdate>20220825</startdate><enddate>20220825</enddate><creator>Morrison Ponce, Daphne</creator><creator>Kitchen, Levi K</creator><creator>Devlin, John J</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>4T-</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6191-643X</orcidid></search><sort><creationdate>20220825</creationdate><title>Cost–Benefit Analysis of Novel Antiviral Ritonavir in the Active Duty U.S. Military Population</title><author>Morrison Ponce, Daphne ; Kitchen, Levi K ; Devlin, John J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c397t-90721194fdfebff3da71ffce9d7331261924b00cddde149e45917ba4c05c87663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antiviral Agents - therapeutic use</topic><topic>Cost-Benefit Analysis</topic><topic>Humans</topic><topic>Military Personnel</topic><topic>Ritonavir - pharmacology</topic><topic>Ritonavir - therapeutic use</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Morrison Ponce, Daphne</creatorcontrib><creatorcontrib>Kitchen, Levi K</creatorcontrib><creatorcontrib>Devlin, John J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Docstoc</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Military medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Morrison Ponce, Daphne</au><au>Kitchen, Levi K</au><au>Devlin, John J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost–Benefit Analysis of Novel Antiviral Ritonavir in the Active Duty U.S. Military Population</atitle><jtitle>Military medicine</jtitle><addtitle>Mil Med</addtitle><date>2022-08-25</date><risdate>2022</risdate><volume>187</volume><issue>9-10</issue><spage>274</spage><epage>275</epage><pages>274-275</pages><issn>0026-4075</issn><eissn>1930-613X</eissn><cop>US</cop><pub>Oxford University Press</pub><pmid>34986240</pmid><doi>10.1093/milmed/usab552</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0002-6191-643X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0026-4075
ispartof Military medicine, 2022-08, Vol.187 (9-10), p.274-275
issn 0026-4075
1930-613X
language eng
recordid cdi_proquest_miscellaneous_2617273924
source MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals
subjects Antiviral Agents - therapeutic use
Cost-Benefit Analysis
Humans
Military Personnel
Ritonavir - pharmacology
Ritonavir - therapeutic use
United States
title Cost–Benefit Analysis of Novel Antiviral Ritonavir in the Active Duty U.S. Military Population
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T00%3A58%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost%E2%80%93Benefit%20Analysis%20of%20Novel%20Antiviral%20Ritonavir%20in%20the%20Active%20Duty%20U.S.%20Military%20Population&rft.jtitle=Military%20medicine&rft.au=Morrison%20Ponce,%20Daphne&rft.date=2022-08-25&rft.volume=187&rft.issue=9-10&rft.spage=274&rft.epage=275&rft.pages=274-275&rft.issn=0026-4075&rft.eissn=1930-613X&rft_id=info:doi/10.1093/milmed/usab552&rft_dat=%3Cproquest_cross%3E2617273924%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2707765489&rft_id=info:pmid/34986240&rft_oup_id=10.1093/milmed/usab552&rfr_iscdi=true